Harreld Julie H, Bratton Emily M, Federico Sara M, Li Xingyu, Grover William, Li Yimei, Kerr Natalie C, Wilson Matthew W, Hoehn Mary E
Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee.
Texas Oculoplastic Consultants, Austin, Texas.
Pediatr Blood Cancer. 2016 Apr;63(4):627-33. doi: 10.1002/pbc.25847. Epub 2015 Nov 24.
Approximately 30% of patients with metastatic (stage M) neuroblastoma present with periorbital ecchymosis from orbital osseous disease. Though locoregional disease is staged by imaging, the prognostic significance of metastatic site in stage M disease is unknown. We hypothesize that, compared to nonorbital metastasis, orbital metastasis is associated with decreased survival in patients with stage M neuroblastoma, and that periorbital ecchymosis reflects location and extent of orbital disease.
Medical records and imaging from 222 patients with stage M neuroblastoma seen at St. Jude Children's Research Hospital between January 1995 and May 2009 were reviewed. Thirty-seven patients were <18 months of age at diagnosis and 185 were ≥18 months of age. Overall survival (OS) and 5-year survival (5YS) were compared for patients with and without orbital, calvarial and nonorbital osseous metastasis, and with and without periorbital ecchymosis (log-rank test). Associations of periorbital ecchymosis with orbital metastasis location/extent were explored (Fisher's exact test, t-test).
In patients ≥18 months of age, only orbital metastasis was associated with decreased 5YS (P = 0.0323) and OS (P = 0.0288). In patients <18 months of age, neither orbital, calvarial, or nonorbital bone metastasis was associated with OS or 5YS. Periorbital ecchymosis was associated with higher number of involved orbital bones (P = 0.0135), but not location or survival.
In patients ≥ 18 months of age with stage M neuroblastoma, orbital metastatic disease is associated with decreased 5YS and OS. In future clinical trials, orbital disease may be useful as an imaging-based risk factor for substratification of stage M neuroblastoma.
约30%的转移性(M期)神经母细胞瘤患者因眼眶骨质病变出现眶周瘀斑。虽然局部区域疾病通过影像学进行分期,但M期疾病中转移部位的预后意义尚不清楚。我们假设,与非眼眶转移相比,眼眶转移与M期神经母细胞瘤患者生存率降低相关,且眶周瘀斑反映了眼眶疾病的位置和范围。
回顾了1995年1月至2009年5月在圣裘德儿童研究医院就诊的222例M期神经母细胞瘤患者的病历和影像学资料。37例患者诊断时年龄小于18个月,185例患者年龄大于或等于18个月。比较有或无眼眶、颅骨和非眼眶骨质转移以及有或无眶周瘀斑患者的总生存期(OS)和5年生存率(5YS)(对数秩检验)。探讨眶周瘀斑与眼眶转移位置/范围的相关性(Fisher精确检验、t检验)。
在年龄大于或等于18个月的患者中,只有眼眶转移与5YS降低(P = 0.0323)和OS降低(P = 0.0288)相关。在年龄小于18个月的患者中,眼眶、颅骨或非眼眶骨转移均与OS或5YS无关。眶周瘀斑与受累眼眶骨数量较多相关(P = 0.0135),但与位置或生存率无关。
在年龄大于或等于18个月的M期神经母细胞瘤患者中,眼眶转移性疾病与5YS和OS降低相关。在未来的临床试验中,眼眶疾病可能作为基于影像学的危险因素用于M期神经母细胞瘤的分层。